ArticleAMB Express2025
Antimicrobial and anti-cancer potential of turmeric synthesized AuNPs and Chitosan-AuNP nanocomposites against MDR pathogens and breast/colorectal carcinoma cells.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Plant Bioactive Compounds at the Interface of Extraction Science, Green Nanoparticles and Applied Biotechnology: A Narrative Review.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The rise in antimicrobial resistance to current antibiotics has driven the search for novel natural compounds with antimicrobial properties. This study aimed at evaluate the Antimicrobial, Anti-Biofilm, and Cytotoxic Potential of Turmeric synthesized AuNPs and Chitosan-AuNP Nanocomposites against MDR urinary tract infections (UTIs) Pathogens (K. pneumoniae and E. coli) and MCF-7 & HCT-116 Cancer Cell Lines. Biosynthesize- characterization of turmeric-gold nanoparticles (TAuNPs) using methanolic extract of Curcuma longa rhizome by Transmission Electron Microscopy (TEM), X-ray spectroscopy, Fourier Transform Infrared (FT-IR) spectroscopy, and Zeta potential (Z-potential) analysis. Coated biosynthesized TAuNPs with biodegradable chitosan to form a chitosan-turmeric gold nanocomposite (NCS-TAuNPs). Phytochemical and gas chromatography-mass spectrometry (GC–MS) analysis were used to investigate the total phenolic and flavonoids contents, and chemical properties of the C. longa extract, assessment the antimicrobial and anti-biofilm efficiency of TAuNPs and NCS-TAuNPs conjugate against K. pneumoniae ESA254 and E. coli ESA253 isolates, evaluation in vitro, the cytotoxicity effects of TAuNPs and NCS-TAuNPs conjugate against MCF-7 cells and HCT-116 cancer cell lines copared with Fluorouracil (5FU) chemical anticancer drug. The results indicated that, presence of high levels (3452 mg QE/100 g DW and 2624 mg GAE/100 g DW) of flavonoids and phenolic contents in C. longa extract, the antioxidant scavenging abilities of 150 μg/mL of TAuNPs and NCS-TAuNPs conjugate against ABTS free radicals were reported 63.72 ± 0.09% and 52.55 ± 0.07% respectively, and 50.29 ± 0.038% and against DPPH free radicals were 68.43 ± 0.095% respectively. The maximum antibacterial activity by inhibiting K. pneumoniae ESA254 and E. coli ESA253 were recorded 15.6 ± 0.2 mm and 13.3 ± 0.20 mm at exposed to 150 µg/mL of NCS –TAuNPs, 14.3 ± 0.3 mm and 10.8 ± 0.23 mm by exposed to 150 µg/mL TAuNPs respectively. The maximum anti-biofilm activity (biofilm reduction %) of K. pneumoniae ESA254 and E. coli ESA253 were recorded 85.67 ± 2.46% and 77.50 ± 2.8% at exposed to 150 µg/mL of NCS –TAuNPs, 63.82 ± 1.89% and 58.07 ± 2.13% by exposed to 150 µg/mL TAuNPs respectively. The anticancer activity of TAuNPs and NCS–TAuNPs conjugate against MCF-7 and HCT-116 cell lines as cell viability %, showed potential cytotoxic effect in MCF-7 cells with IC50 values 38.77 ± 3.1 μg/mL and 36.31 ± 2.9 μg/mL exposed to 150 μg/mL of NCS–TAuNPs and TAuNPs respectively, and 41.26 ± 1.9 μg/mL and 39.85 ± 2.7 μg/mL in HCT-116 cell exposed to 150 μg/mL of NCS–TAuNPs and TAuNPs respectively. The study concluded that, the resulting biosynthesized TAuNPs and NCS–TAuNPs nanocomposite exhibited novel potential dual- anaotherapeutic efficiency combating MDR UTI pathogens and cancer treatment, the safe and biocompatible chitosan nanoconjugate is drug carriers with intelligent therapeutic platform, offering synergistic efficacy to AuNPs as anticancer and antibacterial agents against MCF-7 and HCT-116 cancer cell lines, against infections caused by K. pneumoniae and E. coli pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.